Dendritic cell-based cancer immunotherapies
Dendritic cell-based cancer immunotherapies
复制标题
DOI：
10.1007/s00005-009-0025-x
复制
发表时间：
2009-05-01
影响因子：
3.2
通讯作者：
Shimizu, Kanako
中科院分区：
文献类型：
--
作者：
Fujii, Shin-ichiro;Takayama, Takuya;Shimizu, Kanako
树突状细胞(DC)因其在连接先天免疫系统和获得性免疫系统中的独特作用，已成为新型免疫疗法的研究热点。然而，使用体外产生的和抗原致敏的DC进行主动免疫的策略在临床试验中显示出有限的效果。这些过去的方法没有考虑到在DC成熟、抗原处理和呈递给初始T细胞期间先天免疫系统细胞和DC之间的复杂相互作用。通过更好地了解在有效免疫反应期间体内发生的事件的自然顺序，我们可以定制抗肿瘤免疫治疗策略，以增强这种反应的各个方面，从天然免疫细胞的激活到抗原摄取和DC成熟，到初始T细胞的启动，最终到抗肿瘤免疫的建立。目前的DC疫苗接种策略利用许多方法来概括最终产生保护性抗肿瘤免疫反应的一连串事件。
Because of their unique role in linking the innate and adaptive immune systems, dendritic cells (DCs) have been a logical focus for novel immunotherapies. However, strategies employing active immunization with ex vivo generated and antigen-pulsed DCs have shown limited efficacy in clinical trials. These past approaches did not take into account the complex interactions between cells of the innate immune system and DCs during DC maturation, antigen processing, and presentation to naive T cells. By better understanding the natural sequence of events occurring in vivo during an effective immune response, we can tailor antitumor immunotherapeutic strategies to augment aspects of this response from the activation of innate immune cells to antigen uptake and DC maturation to priming of naive T cells and, ultimately, to the establishment of antitumor immunity. Current DC vaccination strategies utilize a number of methods to recapitulate the cascade of events that culminate in a protective antitumor immune response.